Article Abstract

DNA damage, tumor mutational load and their impact on immune responses against cancer

Authors: Michalis Liontos, Ioannis Anastasiou, Aristotelis Bamias, Meletios-Athanasios Dimopoulos

Abstract

Advances in immunotherapy have changed the therapeutic landscape in many malignancies. Immune checkpoint inhibitors have already received regulatory approval in melanomas, lung, renal and bladder carcinomas. A common feature of these neoplasms is the increased mutational load, related to a possible increase number of tumor neoantigens that are recognized by the immune system. The mechanisms that DNA damage could confer to the mutational load and the formation of neoantigens and how this could be exploited to advance our immunotherapeutic strategies is discussed in this review.

Refbacks

  • There are currently no refbacks.

Article Options

Download Citation